Mersana Therapeutics Stock Today
| MRSN Stock | USD 2.04 0.06 3.03% |
Performance6 of 100
| Odds Of DistressOver 54
|
Mersana Therapeutics is selling at 2.04 as of the 24th of November 2024; that is 3.03 percent increase since the beginning of the trading day. The stock's open price was 1.98. Mersana Therapeutics has 54 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Mersana Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of September 2024 and ending today, the 24th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of June 2017 | Category Healthcare | Classification Health Care |
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates for cancer patients with unmet need. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. Mersana Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 123.53 M outstanding shares of which 9.87 M shares are now shorted by private and institutional investors with about 14.04 trading days to cover. More on Mersana Therapeutics
Moving against Mersana Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Mersana Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Martin MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMersana Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mersana Therapeutics' financial leverage. It provides some insight into what part of Mersana Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mersana Therapeutics (MRSN) is traded on NASDAQ Exchange in USA. It is located in 840 Memorial Drive, Cambridge, MA, United States, 02139 and employs 123 people. Mersana Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 252.01 M. Mersana Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 123.53 M outstanding shares of which 9.87 M shares are now shorted by private and institutional investors with about 14.04 trading days to cover.
Mersana Therapeutics currently holds about 225.13 M in cash with (168.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Mersana Therapeutics Probability Of Bankruptcy
Ownership AllocationMersana Therapeutics maintains a total of 123.53 Million outstanding shares. The majority of Mersana Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Mersana Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Mersana Therapeutics. Please pay attention to any change in the institutional holdings of Mersana Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Mersana Ownership Details
Mersana Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 2.4 M | |
| Schonfeld Strategic Advisors Llc | 2024-09-30 | 2.2 M | |
| Jpmorgan Chase & Co | 2024-06-30 | 2 M | |
| Boxer Capital Llc | 2024-09-30 | 1.8 M | |
| Deutsche Bank Ag | 2024-06-30 | 1.6 M | |
| Woodline Partners Lp | 2024-06-30 | 1.5 M | |
| 5am Venture Management, Llc | 2024-09-30 | 1.3 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 1.2 M | |
| Longwood Capital Partners Llc | 2024-09-30 | 1.2 M | |
| Ecor1 Capital, Llc | 2024-09-30 | 19.4 M | |
| Nextech Invest Ag | 2024-09-30 | 12.1 M |
Mersana Therapeutics Historical Income Statement
Mersana Stock Against Markets
Mersana Therapeutics Corporate Management
| Chuck Miller | Senior Affairs | Profile | |
| Carla Poulson | Chief Officer | Profile | |
| Marc Damelin | Oncology, Biology | Profile | |
| Jason Fredette | Senior Communications | Profile | |
| Mohan Bala | Senior Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.60) | Revenue Per Share 0.286 | Quarterly Revenue Growth 0.637 | Return On Assets (0.26) | Return On Equity (2.13) |
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.